Sartorius Stedim Biotech Expands PAT Portfolio by Adding Sensor Technology for Real-Time Biomass Measurement
SSB has entered into a global sales and development partnership with Aber Instruments (Aber)
Sartorius Stedim Biotech (SSB), a leading international supplier for the pharmaceutical and biotech industries, has entered into a global sales and
development partnership with Aber Instruments (Aber), a Welsh company for bioprocess and brewing equipment. Aber is a highly specialized supplier of sensor technology that is used by the biopharmaceutical industry for in-line biomass measurement in cell cultivation and fermentation processes.
Based on this cooperation, SSB has secured exclusive global marketing and distribution rights to Aber‘s single-use sensor technology for the biopharmaceutical market. As agreed, Aber will supply SSB with measuring instruments. SSB will manufacture the biomass sensors under
licence, integrate these into its single-use bioreactors and exclusively market these products in a dual-branding arrangement. New single-use sensors will be developed by both companies.
SSB has continuously expanded its process analytics portfolio over the past years in the area of single-use sensors to enable real-time, non-invasive measurement of critical process parameters such as pH, dissolved oxygen content, temperature, glucose, lactate and biomass. “Single-use sensors make our disposable bags even more intelligent,” comments Stefan Schlack, Senior Vice President of Marketing at SSB. “They deliver real-time information about the progress of cell culture processes and help biopharmaceutical customers to understand their processes even better and further optimize them – a decisive competitive advantage.“
In-line biomass sensors enable precise and reproducible information to be obtained on the progress of a fermentation process, without having to take samples and analyze these in the laboratory. As a result, cells are not unnecessarily exposed to stress caused by manual sampling and contamination risks are eliminated. In conjunction with SSB‘s existing PAT and software solutions, biomass sensors represent high-performance
tools for modeling and optimizing biopharmaceutical development and manufacturing processes, as well as for further accelerating development times.
Dr. John Carvell, Sales and Marketing Director at Aber Instruments, is pleased about collaborating with SSB: “Based on SSB’s global sales and distribution network, we can make our technology accessible to an even wider group of customers. SSB has in-depth expertise in single-use technology and is thoroughly versed in bioprocesses. Together with our profound knowledge of in-line biomass measurement, both companies stand to benefit from the joint development of new sensors.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance